Gastroenterology Doctors in Bountiful, UT - Medicare Status, Address, Contact

1 Gastroenterology doctors found. Showing 1 - 1

Dr. Christopher Canale, MD
Internal Medicine - Gastroenterology
Medicare: Accepting Medicare Assignments
Practice Location: 620 East Medical Drive, Suite 205, Bountiful, UT 84010
Phone: 801-298-0057 Fax: 801-298-9765

News Archive

Biomarker Discovery Service from Arrayit to unravel mystery of genetic links for human disease states

Arrayit Corporation (OTCBB: ARYC), a proprietary life sciences technology leader, is making available a Biomarker Discovery Service capable of identifying multiple new major genetic links for human disease states which have remained a mystery for years. In separate technology collaborations, Arrayit has conducted confidential experiments which have successfully proven the unique capabilities of the custom Arrayit products and protocols employed in the Biomarker Discovery Service.

JPND invites proposals from researchers to understand the underlying causes of neurodegenerative diseases

The EU Joint Programme - Neurodegenerative Disease Research (JPND) is inviting calls for proposals from research teams across Europe to increase understanding of the factors that put people at risk of developing neurodegenerative diseases (ND) such as Alzheimer's and also to evaluate health and social care strategies for people living with these debilitating illnesses.

Merck, Cardiome Pharma show superiority of BRINAVESS to amiodarone injection

In a new Phase III study, BRINAVESSTM (vernakalant) intravenous, an investigational compound being developed in the European Union by Merck (known as MSD outside the USA and Canada) and Cardiome Pharma Corp. to treat atrial fibrillation, showed that BRINAVESS was superior to amiodarone injection, in converting patients' heart rate from atrial fibrillation (AF) to sinus rhythm (SR) within 90 minutes of the start of administration.

Empagliflozin reduces CKD progression in type 2 diabetics with cardiovascular disease

Empagliflozin (EMPA), a selective inhibitor of sodium/glucose cotransporter 2 (SGLT2 inhibitors, "gliflozines"), reduces CKD progression in type 2 diabetics (T2D) with cardiovascular disease, presumably by lowering intraglomerular pressure.

Cipher Pharmaceuticals reaches cumulative sales milestone for Lipofen

Cipher Pharmaceuticals Inc. today announced that it reached a cumulative sales milestone for Lipofen, the Company's fenofibrate product. Achieving this target triggers a US$1.0 million milestone payment from Kowa Pharmaceuticals America Inc., Cipher's U.S. marketing and distribution partner, which will be reflected in Cipher's revenue for the second quarter of fiscal 2010.

Gastroenterology Doctors in Bountiful, UT Accepting Medicare